Mohammad O. Atiq, Ashley Page, Meghan Catenacci, Akash Patnaik, Gladell P. Paner, Scott E. Eggener, Russell Zelig Szmulewitz. "High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.tps415